ANSWERS TO YOUR MOST PRESSING QUESTIONS

FAQs

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.2

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified
healthcare professional.

EUFLEXXA works in 2 ways to keep you moving forward.2-5

Lubricates & Cushions2-4

Helps with increased shock absorption

Reduces Inflammation & Pain2-5

Protects cartilage

Helps produce natural HA found in the body

It does! In fact, EUFLEXXA is the HA injection that most closely resembles the natural, healthy HA in your knee.2,6-11

In a 12-week clinical trial*:

Patients treated with EUFLEXXA experienced powerful pain relief† as early as 1-week after the first injection, which continued to improve after each one.2,12

Additionally, Nearly 2/3 of EUFLEXXA patients were PAIN-FREE
at the end of the 12-week study12

Pain-free is defined as symptom-free for the 5 WOMAC pain questions (with average visual analog scale [VAS] scores of <20mm).

*Questions based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). WOMAC is an internationally recognized and widely used set of standardized questionnaires that allow healthcare providers to assess the condition of patients with osteoarthritis of the knee and hip. Measures include pain, stiffness, and physical functioning of the joints.

†Based on % reduction in Western Ontario and McMaster Universities Osteoarthritis Index pain score from baseline in a pivotal, 12-week trial of EUFLEXXA (n=157) vs Synvisc (n=158). Improvements from baseline were statistically significant for both treatment groups. EUFLEXXA = 101/160.

Pain relief can begin as early as a week after your first injection and continues to improve after each injection for up to 6 months.2,12

The most common adverse reactions reported in a clinical trial of EUFLEXXA were joint pain, back pain, limb pain, muscle pain, and joint swelling.2

EUFLEXXA is 3 injections given into the knee joint by your doctor. Each injection should be given 1 week apart.2

EUFLEXXA is the HA injection that most closely resembles the natural, healthy HA in your knee.
By working in 2 ways, it helps lubricate and cushion your knee while reducing inflammation and pain.2-11

In fact, a 12-week clinical trial* showed that patients treated with EUFLEXXA experienced pain relief† after the first injection, which continued to improve after each one. Nearly 2/3 of EUFLEXXA patients were PAIN-FREE at the end of the 12-week study.2,12

Pain-free is defined as symptom-free for the 5 WOMAC pain questions (with average visual analog scale [VAS] scores of <20mm).

See what you can expect by watching a real patient’s experience with EUFLEXXA.

*Questions based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). WOMAC is an internationally recognized and widely used set of standardized questionnaires that allow healthcare providers to assess the condition of patients with osteoarthritis of the knee and hip. Measures include pain, stiffness, and physical functioning of the joints.

†Based on % reduction in Western Ontario and McMaster Universities Osteoarthritis Index pain score from baseline in a pivotal, 12-week trial of EUFLEXXA (n=157) vs Synvisc (n=158). Improvements from baseline were statistically significant for both treatment groups. EUFLEXXA = 101/160.

Yes. Repeat treatment with EUFLEXXA was proven well-tolerated for an additional 6 months. That’s why it’s important to stay ahead of the pain and follow-up with your doctor 6 months after your third injection to schedule another course of EUFLEXXA.2,13,14

Yes. Ask your doctor what will work best for you.2

While injection pain is individual, your doctor may discuss options to numb your knee before EUFLEXXA is given to offset any potential discomfort.

It’s important to follow these 3 steps2:

  1. Avoid physical activity for 48 hours, including standing for more than 1 hour at a time

  2. Ice your knee if you have any mild pain or swelling
    If you experience joint pain, back pain, limb/muscle pain, or joint swelling, or any other problems, call your doctor right away

  3. Ask your doctor when you can begin major physical activities again

EUFLEXXA offers various types of coverage to help meet your needs.

  • 100% coverage on Medicare Part B* without restrictions
  • ~50% of commercially insured patients pay a $0 copay1
  • Coverage for patients with no insurance through the
    EUFLEXXA Patient Direct Program

Not sure what type of coverage you have? Find out here

*Out-of-pocket cost may apply. Please check with your doctor.

EUFLEXXA has a wide-range of support including:

  • The EUFLEXXA Commitment Program
  • Educational materials to help you understand more about OA of the knee and your treatment
  • Tools to help you find a doctor near you that can help treat your OA knee pain

About EUFLEXXA

Find out how EUFLEXXA stands apart.

See the Difference

What to Expect

See what you can expect throughout treatment with EUFLEXXA

Learn More
  1. Rolling 12 month average of IQVIA claims data based on unique patients (December 2022).
  2. EUFLEXXA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.
  3. Altman R, et al. Anti-inflammatory effects of intra-articular hyaluronic acid: a systematic review. Cartilage. 2019;10(1):43-52.
  4. Altman RD, Manjoo A, Fierlinger A, et al. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskeletal Disorders. 2015;16:321.
  5. Yang C, Cao M, Liu H, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem. 2012;287(51):43094-43107.
  6. Nicholls M, et al. A comparison between rheological properties of intra-articular hyaluronic acid preparations and reported human synovial fluid. Adv Ther. 2018;35:523-530.
  7. Orthovisc [package insert]. Woburn, MA: Anika Therapeutics, Inc; 2005.
  8. Supartz [package insert]. Durham, NC: Bioventus LLC; 2012.
  9. Gelsyn-3 [package insert]. Durham, NC: Bioventus LLC; 2016.
  10. Hyalgan [package insert]. Parsippany, NJ: Fidia Pharma USA Inc; 2011.
  11. Genvisc-850 [package insert]. Doylestown, PA: OrthogenRx; 2016.
  12. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-162.
  13. Altman RD, Rosen JE, Bloch DA, et al. A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX Trial). Semin Arthritis Rheum. 2009;39(1):1-9.
  14. Altman RD, Rosen JE, Bloch DA, et al. Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. Osteoarthritis Cartilage. 2011;19(10):1169-1175.

Please see Important Safety Information and Full Prescribing Information

Indication

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.

Important Safety Information

  • Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.
  • You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.
  • EUFLEXXA has not been tested in pregnant women, women who are nursing or in children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time.)
  • The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.

Indication

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.

Important Safety Information

  • Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.
  • You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.
  • EUFLEXXA has not been tested in pregnant women, women who are nursing or in children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time.)
  • The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

Please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.

 

The content on this website is for informational purposes only and is not intended to replace a discussion with a healthcare professional.

Get a head start: Check your coverage and sign up for your EUFLEXXA coverage certificate

Check your coverage below to see if you may be covered through your insurance provider for EUFLEXXA

EUFLEXXA is covered on Medicare Part B*, and is covered by most private plans. Your healthcare provider’s office will check your benefits.

Your EUFLEXXA coverage certificate will let you know if you are covered. Bring your certificate to your doctor to discuss EUFLEXXA as a possible treatment option for you.

MM slash DD slash YYYY
Address(Required)

By signing up, I am giving Ferring Pharmaceuticals Inc. (“Ferring”) permission to store and use the information that I have provided. I understand and agree that my information will be used by Ferring (or companies working on Ferring’s behalf) to contact me by telephone, email, or mail to provide me with information about products or services that may be of interest to me. I understand that my information will be treated as described in Ferring’s Privacy Notice, which provides details about my privacy rights. Also, I understand that I may opt out of the database at any time by making the request at Data Subject Form, or by calling 1-888-FERRING, Monday through Friday, 8 AM to 7 PM ET to speak to a representative or leave a voicemail. This statement may be updated from time to time.

This program assists in the determination of whether treatment could be covered by the applicable third-party payer based on coverage guidelines provided by the payer and patient information provided by you. Third-party reimbursement is affected by many factors. Therefore, we make no representation or guarantee that full or partial insurance reimbursement or any other payment will be available. This is not intended to be medical advice. Please consult with your healthcare provider to determine which treatment may be right for you.

*Out-of-pocket cost may apply. Please check with your doctor.

This website may contain links to, or be accessed from links on, other worldwide websites. Ferring does not have responsibility for or control the contents, availability, operation or performance of other websites to which this website may be linked or from which this website may be accessed.

Ferring makes no representation regarding the content of any other websites which you may access from this website.

Ok Cancel